AltAssets is the private equity news and research service from Almeida Capital
AltAssets HomeAlmeida Capital websiteAlmeida Capital

 

PRINT THIS PAGE

Nanotechnology: hype, hope & home runs

07/01/2003Source:Lux Capital. Josh Wolfe 

Venture capitalists are constantly on the look-out for new and exciting investment opportunities in developing industries. One such sector is nanotechnology, the science of the truly tiny. Josh Wolfe of Lux Capital assesses the development of the sector and what may lie in store for the future.

Nanotechnology is constantly developing as scientists discover or create smaller and more complex structures and tools. It is also increasingly attracting attention from respective governments as its potential becomes more obvious.


Copyright © 2002 Lux Capital

Click here to view full report (pdf 980kb)

You need Adobe Acrobat to read this document. If you do not have it, you can download it free from www.adobe.com/products/acrobat/readstep.html

Josh Wolfe is a co-founder and managing partner of Lux Capital.

Lux Capital is a venture capital firm focused on identifying and building early-stage technology businesses. For more information please visit www.luxcapital.com

top of the page

  Advanced Search

HOME | ABOUT US | CONTRIBUTE | FAQ | ADVERTISING | RSS FEED | WEEKLY NEWSLETTER SIGN-UP | CONTACT US

All rights reserved. This document and its content are for your personal, non-commercial use only. No further copying, reproduction, distribution, transmission, display of AltAssets content is allowed. To obtain permission please contact editorial@altassets.com. You may not alter or remove the copyright or any other statements from copies of the content.

AltAssets is a service offered by Almeida Capital's Research Division. Available online at www.AltAssets.net
Almeida Capital Ltd is regulated by FSA and registered in England (no. 3945728). Registered Office: Acre House, 11-15 William Road, London NW1 3ER. Legals & Terms of Use
Content is © AltAssets 2000-2008

Subscribe to our newsletter Subscribe to our newsletter